Ratio Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Design Center Pl Ste 19-601, Boston, M...Phone Number
(617) 371-8898Website
www.ratiotx.comRevenue
$13.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ratio Therapeutics
Ratio Therapeutics is a biopharmaceutical company focused on developing targeted radiopharmaceuticals for the treatment of cancer. Its platform combines proprietary targeting scaffolds, pharmacokinetic modulation, and advanced chelation technologies to create small-molecule agents designed to selectively target cancer cells while carrying either imaging or therapeutic radioisotopes. The company uses a theranostic approach, pairing diagnostic imaging with targeted radiotherapy to support the identification and development of promising drug candidates. Its work brings together expertise across drug discovery, engineering, clinical research, and radiopharmaceutical development, with the goal of advancing more precise and effective cancer treatments.Explore more
Ratio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ratio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Ratio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ratio Therapeutics launches new products
Check out if Ratio Therapeutics is spiking on competitors!
Click to see if Ratio Therapeutics had a recent Job posting/layoffs
Ratio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ratio Therapeutics has new funding data
Earning: See what the market has to say on Ratio Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Ratio Therapeutics
Recommended Actions
Find VP level buyers at Ratio Therapeutics
Find 3 more new buyers
Compare Similar Companies to Ratio Therapeutics
Compare insights from companies similar to Ratio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ratio Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ratio Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ratio Therapeutics.
Ratio Therapeutics financials insights
Gather financial insights about Ratio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Seed
$20M
2023
Series A
$20M
2024
Series B
$50M
2026
Series C
$70M
Ratio Therapeutics Tech Stack
A closer look at the technologies used by Ratio Therapeutics
Most Recent Scoops
Funding
Funding
Partnership
Partnership, Product Management, Business Development, Capacity Planning, Pharmaceuticals, Manufacturing Operations
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Ratio Therapeutics News & Media
/C O R R E C T I O N -- Ratio Therapeutics Inc./
In the news release, Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs, issued 30-Jun-2026 by Ratio Therapeutics Inc. over PR Newswire, we are advised by the company that changes have been made. The complete,...PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
IDAHO FALLS, Idaho, May 29, 2026 /PRNewswire/ -- PharmaLogic Holdings Corp., ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announced an expansion of its manufacturing partnership with Ratio...Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio's lead FAP-targeted radiotherapeutic candidate BOSTON, May 29, 2026 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing...Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer
BOSTON, March 12, 2026 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ratio Therapeutics
Sign Up For FreeTo access detailed company insights
Ratio Therapeutics is a biopharmaceutical company focused on developing targeted radiopharmaceuticals for the treatment of cancer. Its platform combines proprietary targeting scaffolds, pharmacokinetic modulation, and advanced chelation technologies to create small-molecule agents designed to selectively target cancer cells while carrying either im... Read More
